Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Other hormonal markers, including follicle-stimulating hormone (FSH), progesterone (PGTR), vitamin D (VIT-D), and androstenedione (ASD), did not demonstrate significant changes within or between groups over time (all p > 0.05).

Source: 3.2. Blood Parameters and Biochemical Markers at Baseline and Endpoint. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Marine Oligo-Fucoidan as a Safe Functional Food for Managing Uterine Fibroids: Results from a Pilot Randomized Controlled Trial

Source: Article title.

This was a randomized, double-blind, placebo-controlled clinical trial conducted at Taipei Medical University Hospital to evaluate the effects of low-molecular-weight fucoidan (LMF, oligo-fucoidan) on the progression of uterine leiomyomas and symptom severity.

Source: Methods.

Participants were randomly assigned to receive either 4 g/day of oligo-fucoidan (treatment group) or a matched dose of cellulose placebo, administered in two divided doses daily.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Marine Oligo-Fucoidan as a Safe Functional Food for Managing Uterine Fibroids: Results from a Pilot Randomized Controlled Trial

Randomised controlled trial · Biomedicines · 2025

Original publication title

Marine Oligo-Fucoidan as a Safe Functional Food for Managing Uterine Fibroids: Results from a Pilot Randomized Controlled Trial

Yi-Fen Chiang; Ko-Chieh Huang; Pei-Shen Huang; Mohamed Ali; Shih-Min Hsia

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Uterine leiomyomas, commonly known as fibroids, are the most prevalent benign tumors in women of reproductive age and a major contributor to gynecological morbidity. Although surgery and hormonal therapies are standard treatments, their associated side effects have prompted the search for safer, non-hormonal alternatives. Oligo-fucoidan, a sulfated polysaccharide derived from brown seaweed, has demonstrated anti-fibrotic and estrogen-regulating effects in preclinical models, but its clinical potential remains largely unexplored.

Methods:

In this randomized, double-blind, placebo-controlled pilot trial, 16 women diagnosed with uterine leiomyomas by ultrasound were enrolled and randomly assigned to receive either oligo-fucoidan (4 g/day) or placebo for six months (n = 8 per group). The primary endpoints were changes in the number of leiomyomas and quality of life, assessed using the World Health Organization Quality-of-Life Scale (WHOQOL-BREF) and Menstrual Distress Questionnaire (MDQ). Hormonal and safety parameters were also monitored.

Results:

Compared with the placebo group, participants receiving oligo-fucoidan exhibited a statistically significant reduction in fibroid number and reported improvements in quality-of-life domains. No serious adverse events occurred, and no clinically significant changes were noted in safety-related laboratory parameters.

Conclusions:

This pilot study provides preliminary clinical evidence that oligo-fucoidan may be a safe, well-tolerated, and potentially effective functional food-based approach for managing uterine fibroids. Larger trials are warranted to confirm these findings.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Uterine leiomyomas, commonly known as fibroids, are the most prevalent benign tumors in women of reproductive age and a major contributor to gynecological morbidity. Although surgery and hormonal therapies are standard treatments, their associated side effects have prompted the search for safer, non-hormonal alternatives. Oligo-fucoidan, a sulfated polysaccharide derived from brown seaweed, has demonstrated anti-fibrotic and estrogen-regulating effects in preclinical models, but its clinical potential remains largely unexplored.

Source: Background:

Abstract: Results

Compared with the placebo group, participants receiving oligo-fucoidan exhibited a statistically significant reduction in fibroid number and reported improvements in quality-of-life domains. No serious adverse events occurred, and no clinically significant changes were noted in safety-related laboratory parameters.

Source: Results:

Abstract: Conclusions

This pilot study provides preliminary clinical evidence that oligo-fucoidan may be a safe, well-tolerated, and potentially effective functional food-based approach for managing uterine fibroids. Larger trials are warranted to confirm these findings.

Source: Conclusions:
Authors’ abstract

Background:

Uterine leiomyomas, commonly known as fibroids, are the most prevalent benign tumors in women of reproductive age and a major contributor to gynecological morbidity. Although surgery and hormonal therapies are standard treatments, their associated side effects have prompted the search for safer, non-hormonal alternatives. Oligo-fucoidan, a sulfated polysaccharide derived from brown seaweed, has demonstrated anti-fibrotic and estrogen-regulating effects in preclinical models, but its clinical potential remains largely unexplored.

Methods:

In this randomized, double-blind, placebo-controlled pilot trial, 16 women diagnosed with uterine leiomyomas by ultrasound were enrolled and randomly assigned to receive either oligo-fucoidan (4 g/day) or placebo for six months (n = 8 per group). The primary endpoints were changes in the number of leiomyomas and quality of life, assessed using the World Health Organization Quality-of-Life Scale (WHOQOL-BREF) and Menstrual Distress Questionnaire (MDQ). Hormonal and safety parameters were also monitored.

Results:

Compared with the placebo group, participants receiving oligo-fucoidan exhibited a statistically significant reduction in fibroid number and reported improvements in quality-of-life domains. No serious adverse events occurred, and no clinically significant changes were noted in safety-related laboratory parameters.

Conclusions:

This pilot study provides preliminary clinical evidence that oligo-fucoidan may be a safe, well-tolerated, and potentially effective functional food-based approach for managing uterine fibroids. Larger trials are warranted to confirm these findings.

Publication and source details

Original title: Marine Oligo-Fucoidan as a Safe Functional Food for Managing Uterine Fibroids: Results from a Pilot Randomized Controlled Trial

Yi-Fen Chiang; Ko-Chieh Huang; Pei-Shen Huang; Mohamed Ali; Shih-Min Hsia

Biomedicines · 2025

* Correspondence: bryanhsia@tmu.edu.tw© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Ministry of Science and Technology, TaiwanMOST 109-2314-B-038-059MOST 110-2314-B-038-158MOST 111-2314-B-038-006Ministry of Science and Technology Council, TaiwanNSTC 113-2811-B-038-040NSTC 112-2320-B-038-010-MY3Hi-Q Marine Biotech International, Taipei, TaiwanA-108-010This work was supported by the Ministry of Science and Technology, Taiwan, grant numbers MOST 109-2314-B-038-059, MOST 110-2314-B-038-158, and MOST 111-2314-B-038-006. This study was supported by the Ministry of Science and Technology Council, Taiwan, grant numbers NSTC 113-2811-B-038-040 and NSTC 112-2320-B-038-010-MY3. This work was financially supported by the Hi-Q Marine Biotech International, Taipei, Taiwan, grant number A-108-010.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:25:49.981530+00:00

DOI: 10.3390/biomedicines13081970 · PMC12383344